AGEN

AGEN1181 (anti-CLTA-4)

Advanced endometrial cancer

Stage (next event)

Expected Date

Phase 2 To be Initiated

TBD

Catalyst Info & Data Links

TITLE: AGEN1181 for Advanced endometrial cancer Phase 1 Readout 


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 1 Readout 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?  

  • TBD


PRIOR DATA

PRESS RELEASES

PRESENTATIONS 

  • 05-2020 (ASCO) AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies. O'Day, et al.

  • 06-2020 (AACR) Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors. Tanne, et al.

POSTERS

Mechanism of Action 

  • To develop AGEN1181, Agenus leveraged the above discovery to modify a part of the antibody known as the Fc region, which interacts with other immune cells to enhance antitumor immunity. In pre-clinical studies, this “Fc-engineered” antibody significantly improved the cross-talk between antigen presenting cells (APCs) and T cells. In cancer immunotherapy, such an interaction is necessary to mount a potent immune response against cancer.

  • multifunctional Fc-engineered next generation anti-CTLA-4 antibody

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Tocagen's Promising Glioblastoma Therapy

AACR 2018 Amp Up

Investors Are Missing An Opportunity With Alkermes

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon